A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus

M. W. Kline, C. V. Fletcher, A. T. Harris, K. D. Evans, R. C. Brundage, R. P. Remmel, N. R. Calles, S. B. Kirkpatrick, C. Simon

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Twelve children infected with the human immunodeficiency virus were treated orally with indinavir, stavudine, plus didanosine for 12 to 48 weeks. Therapy was limited in some cases by nonadherence, intolerance, toxicity, and virologic failure. Marked increases in CD4+ lymphocyte counts and decreases in plasma human immunodeficiency virus RNA concentrations suggest that the regimen has potent antiviral activity.

Original languageEnglish (US)
Pages (from-to)543-546
Number of pages4
JournalJournal of Pediatrics
Volume132
Issue number3 I
DOIs
StatePublished - Jan 1 1998

Fingerprint

Indinavir
Stavudine
Didanosine
HIV
CD4 Lymphocyte Count
Antiviral Agents
RNA
Therapeutics

Cite this

A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus. / Kline, M. W.; Fletcher, C. V.; Harris, A. T.; Evans, K. D.; Brundage, R. C.; Remmel, R. P.; Calles, N. R.; Kirkpatrick, S. B.; Simon, C.

In: Journal of Pediatrics, Vol. 132, No. 3 I, 01.01.1998, p. 543-546.

Research output: Contribution to journalArticle

Kline, M. W. ; Fletcher, C. V. ; Harris, A. T. ; Evans, K. D. ; Brundage, R. C. ; Remmel, R. P. ; Calles, N. R. ; Kirkpatrick, S. B. ; Simon, C. / A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus. In: Journal of Pediatrics. 1998 ; Vol. 132, No. 3 I. pp. 543-546.
@article{c67848270d8446f6a2efb3abd0f40e55,
title = "A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus",
abstract = "Twelve children infected with the human immunodeficiency virus were treated orally with indinavir, stavudine, plus didanosine for 12 to 48 weeks. Therapy was limited in some cases by nonadherence, intolerance, toxicity, and virologic failure. Marked increases in CD4+ lymphocyte counts and decreases in plasma human immunodeficiency virus RNA concentrations suggest that the regimen has potent antiviral activity.",
author = "Kline, {M. W.} and Fletcher, {C. V.} and Harris, {A. T.} and Evans, {K. D.} and Brundage, {R. C.} and Remmel, {R. P.} and Calles, {N. R.} and Kirkpatrick, {S. B.} and C. Simon",
year = "1998",
month = "1",
day = "1",
doi = "10.1016/S0022-3476(98)70039-3",
language = "English (US)",
volume = "132",
pages = "543--546",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "3 I",

}

TY - JOUR

T1 - A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus

AU - Kline, M. W.

AU - Fletcher, C. V.

AU - Harris, A. T.

AU - Evans, K. D.

AU - Brundage, R. C.

AU - Remmel, R. P.

AU - Calles, N. R.

AU - Kirkpatrick, S. B.

AU - Simon, C.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Twelve children infected with the human immunodeficiency virus were treated orally with indinavir, stavudine, plus didanosine for 12 to 48 weeks. Therapy was limited in some cases by nonadherence, intolerance, toxicity, and virologic failure. Marked increases in CD4+ lymphocyte counts and decreases in plasma human immunodeficiency virus RNA concentrations suggest that the regimen has potent antiviral activity.

AB - Twelve children infected with the human immunodeficiency virus were treated orally with indinavir, stavudine, plus didanosine for 12 to 48 weeks. Therapy was limited in some cases by nonadherence, intolerance, toxicity, and virologic failure. Marked increases in CD4+ lymphocyte counts and decreases in plasma human immunodeficiency virus RNA concentrations suggest that the regimen has potent antiviral activity.

UR - http://www.scopus.com/inward/record.url?scp=0031894889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031894889&partnerID=8YFLogxK

U2 - 10.1016/S0022-3476(98)70039-3

DO - 10.1016/S0022-3476(98)70039-3

M3 - Article

C2 - 9544920

AN - SCOPUS:0031894889

VL - 132

SP - 543

EP - 546

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 3 I

ER -